Seattle Genetics: Annual Report 2014 (Seattle Genetics, Inc) - Mar 28, 2015 - Anticipated patent expiry in US and Europe between 2024 and 2030; Anticipated patent term extension for certain methods of treatment using SGN-CD70A in US and Europe until 2031
Anticipated patent expiry • Oncology
|